These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
497 related articles for article (PubMed ID: 16483268)
1. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. DeVault KR Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():33-9. PubMed ID: 16483268 [TBL] [Abstract][Full Text] [Related]
2. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux. Miner PB Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267 [TBL] [Abstract][Full Text] [Related]
3. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients. Bytzer P; van Zanten SV; Mattsson H; Wernersson B Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764 [TBL] [Abstract][Full Text] [Related]
4. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups. Shapiro M; Green C; Faybush EM; Esquivel RF; Fass R Aliment Pharmacol Ther; 2006 Jan; 23(2):321-9. PubMed ID: 16393313 [TBL] [Abstract][Full Text] [Related]
5. [Non-erosive gastroesophageal reflux disease. Incidence of clinical forms, characteristics of esophageal exposure to acid and symptomatic correlations]. Soto Pérez JC; Icaza ME; Vargas F; Valdovinos Díaz MA Rev Gastroenterol Mex; 2003; 68(2):113-9. PubMed ID: 15127647 [TBL] [Abstract][Full Text] [Related]
6. Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment. Miner P Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():20-9. PubMed ID: 15496215 [TBL] [Abstract][Full Text] [Related]
8. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole. Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G; Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305 [TBL] [Abstract][Full Text] [Related]
10. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? Wit NJ; Boer WA; Geldof H; Hazelhoff B; Bergmans P; Tytgat GN; Smout AJ Aliment Pharmacol Ther; 2004 Aug; 20(4):451-8. PubMed ID: 15298640 [TBL] [Abstract][Full Text] [Related]
11. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Malfertheiner P; Lind T; Willich S; Vieth M; Jaspersen D; Labenz J; Meyer-Sabellek W; Junghard O; Stolte M Gut; 2005 Jun; 54(6):746-51. PubMed ID: 15888776 [TBL] [Abstract][Full Text] [Related]
12. Gastroesophageal reflux disease symptoms on antisecretory therapy: acid, non-acid, or no GERD. Katz PO Rev Gastroenterol Disord; 2006; 6(3):136-45. PubMed ID: 16957654 [TBL] [Abstract][Full Text] [Related]
13. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Robinson M; Fitzgerald S; Hegedus R; Murthy A; Jokubaitis L; Aliment Pharmacol Ther; 2002 Mar; 16(3):445-54. PubMed ID: 11876697 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Miwa H; Sasaki M; Furuta T; Koike T; Habu Y; Ito M; Fujiwara Y; Wada T; Nagahara A; Hongo M; Chiba T; Kinoshita Y; Aliment Pharmacol Ther; 2007 Jul; 26(1):69-77. PubMed ID: 17555423 [TBL] [Abstract][Full Text] [Related]
15. [Oesophageal acid exposure test in non-erosive gastroesophageal reflux disease and the diagnostic value of rabeprazole]. Fan YH; Lü B; Zhan LX; Zhang L Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):475-7. PubMed ID: 17663823 [TBL] [Abstract][Full Text] [Related]
17. pH, healing rate, and symptom relief in patients with GERD. Huang JQ; Hunt RH Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580 [TBL] [Abstract][Full Text] [Related]
18. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Nojkov B; Rubenstein JH; Adlis SA; Shaw MJ; Saad R; Rai J; Weinman B; Chey WD Aliment Pharmacol Ther; 2008 Mar; 27(6):473-82. PubMed ID: 18194508 [TBL] [Abstract][Full Text] [Related]
19. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD study. Malfertheiner P; Nocon M; Vieth M; Stolte M; Jaspersen D; Koelz HR; Labenz J; Leodolter A; Lind T; Richter K; Willich SN Aliment Pharmacol Ther; 2012 Jan; 35(1):154-64. PubMed ID: 22070159 [TBL] [Abstract][Full Text] [Related]
20. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole. Frazzoni M; Manno M; De Micheli E; Savarino V Dig Liver Dis; 2006 Feb; 38(2):85-90. PubMed ID: 16289976 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]